Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Corticorelin (Acthrel) vs Cosyntropin (Cortrosyn)
An educational, source-based comparison of Corticorelin (Acthrel) and Cosyntropin (Cortrosyn) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic ovine CRH for differential diagnosis of Cushing's syndrome.
Synthetic ovine corticotropin-releasing hormone (oCRH) that stimulates pituitary ACTH release; used in inferior petrosal sinus sampling and peripheral CRH stimulation testing to distinguish pituitary from ectopic ACTH-dependent Cushing's syndrome.
- Differential diagnosis of ACTH-dependent Cushing's syndrome
- • FDA-approved.
- • Transient flushing, dyspnea, hypotension possible.
Synthetic peptide containing the first 24 amino acids of ACTH — retains full corticotropic activity. Stimulates adrenal cortisol release for diagnostic testing.
- Primary and secondary adrenal insufficiency diagnosis
- • FDA-approved.
- • Single diagnostic dose; very well tolerated.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Corticorelin (Acthrel) | CRH stimulation and IPSS in Cushing's | JCEM | 1991 | Improved discrimination of pituitary vs ectopic ACTH sources. |
| Cosyntropin (Cortrosyn) | Low-dose vs standard cosyntropin stimulation | JCEM | 2008 | Comparison of 1 mcg vs 250 mcg testing for secondary adrenal insufficiency. |
Side-effect & safety grid
- FDA-approved.
- Transient flushing, dyspnea, hypotension possible.
- FDA-approved.
- Single diagnostic dose; very well tolerated.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Corticorelin (Acthrel) vs Cosyntropin (Cortrosyn) — Key differences
- Class: Corticorelin (Acthrel) is classified as CRH Analog · Diagnostics, while Cosyntropin (Cortrosyn) is Diagnostic · Endocrine.
- Primary research focus: Corticorelin (Acthrel) — differential diagnosis of acth-dependent cushing's syndrome; Cosyntropin (Cortrosyn) — primary and secondary adrenal insufficiency diagnosis.
- Tag: FDA-Approved · Diagnostics vs FDA-Approved · Diagnostic.